A randomized controlled Phase Ib trial of the malaria vaccine candidate GMZ2 in African children

Sabine Bélard; Saadou Issifou; Aurore B Hounkpatin; Frieder Schaumburg; Ulysse Ateba Ngoa; Meral Esen; Rolf Fendel; Pablo Martinez de Salazar; Raymund E Mürbeth; Paul Milligan; Nathalie Imbault; Egeruan Babatunde Imoukhuede; Michael Theisen; Søren Jepsen; Ramadhani A Noor; Brenda Okech; Peter G Kremsner; Benjamin Mordmüller

doi:10.1371/journal.pone.0022525

A randomized controlled Phase Ib trial of the malaria vaccine candidate GMZ2 in African children

Sabine Bélard, Saadou Issifou, Aurore B Hounkpatin, Frieder Schaumburg, Ulysse Ateba Ngoa, Meral Esen, Rolf Fendel, Pablo Martinez de Salazar, Raymund E Mürbeth, Paul Milligan, Nathalie Imbault, Egeruan Babatunde Imoukhuede, Michael Theisen, Søren Jepsen, Ramadhani A Noor, Brenda Okech, Peter G Kremsner, Benjamin Mordmüller

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

61 Citationer (Scopus)

Abstract

GMZ2 is a fusion protein of Plasmodium falciparum merozoite surface protein 3 (MSP3) and glutamate rich protein (GLURP) that mediates an immune response against the blood stage of the parasite. Two previous phase I clinical trials, one in naïve European adults and one in malaria-exposed Gabonese adults showed that GMZ2 was well tolerated and immunogenic. Here, we present data on safety and immunogenicity of GMZ2 in one to five year old Gabonese children, a target population for future malaria vaccine efficacy trials.

Originalsprog	Engelsk
Tidsskrift	P L o S One
Vol/bind	6
Udgave nummer	7
Sider (fra-til)	e22525
ISSN	1932-6203
DOI	https://doi.org/10.1371/journal.pone.0022525
Status	Udgivet - 2011

Adgang til dokumentet

10.1371/journal.pone.0022525

Citationsformater

Bélard, S., Issifou, S., Hounkpatin, A. B., Schaumburg, F., Ngoa, U. A., Esen, M., Fendel, R., de Salazar, P. M., Mürbeth, R. E., Milligan, P., Imbault, N., Imoukhuede, E. B., Theisen, M., Jepsen, S., Noor, R. A., Okech, B., Kremsner, P. G., & Mordmüller, B. (2011). A randomized controlled Phase Ib trial of the malaria vaccine candidate GMZ2 in African children. P L o S One, 6(7), e22525. https://doi.org/10.1371/journal.pone.0022525

A randomized controlled Phase Ib trial of the malaria vaccine candidate GMZ2 in African children. / Bélard, Sabine; Issifou, Saadou; Hounkpatin, Aurore B; Schaumburg, Frieder; Ngoa, Ulysse Ateba; Esen, Meral; Fendel, Rolf; de Salazar, Pablo Martinez; Mürbeth, Raymund E; Milligan, Paul; Imbault, Nathalie; Imoukhuede, Egeruan Babatunde; Theisen, Michael; Jepsen, Søren; Noor, Ramadhani A; Okech, Brenda; Kremsner, Peter G; Mordmüller, Benjamin.

I: P L o S One, Bind 6, Nr. 7, 2011, s. e22525.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Bélard, S, Issifou, S, Hounkpatin, AB, Schaumburg, F, Ngoa, UA, Esen, M, Fendel, R, de Salazar, PM, Mürbeth, RE, Milligan, P, Imbault, N, Imoukhuede, EB, Theisen, M, Jepsen, S, Noor, RA, Okech, B, Kremsner, PG & Mordmüller, B 2011, 'A randomized controlled Phase Ib trial of the malaria vaccine candidate GMZ2 in African children', P L o S One, bind 6, nr. 7, s. e22525. https://doi.org/10.1371/journal.pone.0022525

Bélard, Sabine ; Issifou, Saadou ; Hounkpatin, Aurore B ; Schaumburg, Frieder ; Ngoa, Ulysse Ateba ; Esen, Meral ; Fendel, Rolf ; de Salazar, Pablo Martinez ; Mürbeth, Raymund E ; Milligan, Paul ; Imbault, Nathalie ; Imoukhuede, Egeruan Babatunde ; Theisen, Michael ; Jepsen, Søren ; Noor, Ramadhani A ; Okech, Brenda ; Kremsner, Peter G ; Mordmüller, Benjamin. / A randomized controlled Phase Ib trial of the malaria vaccine candidate GMZ2 in African children. I: P L o S One. 2011 ; Bind 6, Nr. 7. s. e22525.

@article{7c3abba95ac942c0879e327f48b9b9de,

title = "A randomized controlled Phase Ib trial of the malaria vaccine candidate GMZ2 in African children",

abstract = "GMZ2 is a fusion protein of Plasmodium falciparum merozoite surface protein 3 (MSP3) and glutamate rich protein (GLURP) that mediates an immune response against the blood stage of the parasite. Two previous phase I clinical trials, one in na{\"i}ve European adults and one in malaria-exposed Gabonese adults showed that GMZ2 was well tolerated and immunogenic. Here, we present data on safety and immunogenicity of GMZ2 in one to five year old Gabonese children, a target population for future malaria vaccine efficacy trials.",

author = "Sabine B{\'e}lard and Saadou Issifou and Hounkpatin, {Aurore B} and Frieder Schaumburg and Ngoa, {Ulysse Ateba} and Meral Esen and Rolf Fendel and {de Salazar}, {Pablo Martinez} and M{\"u}rbeth, {Raymund E} and Paul Milligan and Nathalie Imbault and Imoukhuede, {Egeruan Babatunde} and Michael Theisen and S{\o}ren Jepsen and Noor, {Ramadhani A} and Brenda Okech and Kremsner, {Peter G} and Benjamin Mordm{\"u}ller",

year = "2011",

doi = "10.1371/journal.pone.0022525",

language = "English",

volume = "6",

pages = "e22525",

journal = "PLoS ONE",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "7",

}

TY - JOUR

T1 - A randomized controlled Phase Ib trial of the malaria vaccine candidate GMZ2 in African children

AU - Bélard, Sabine

AU - Issifou, Saadou

AU - Hounkpatin, Aurore B

AU - Schaumburg, Frieder

AU - Ngoa, Ulysse Ateba

AU - Esen, Meral

AU - Fendel, Rolf

AU - de Salazar, Pablo Martinez

AU - Mürbeth, Raymund E

AU - Milligan, Paul

AU - Imbault, Nathalie

AU - Imoukhuede, Egeruan Babatunde

AU - Theisen, Michael

AU - Jepsen, Søren

AU - Noor, Ramadhani A

AU - Okech, Brenda

AU - Kremsner, Peter G

AU - Mordmüller, Benjamin

PY - 2011

Y1 - 2011

N2 - GMZ2 is a fusion protein of Plasmodium falciparum merozoite surface protein 3 (MSP3) and glutamate rich protein (GLURP) that mediates an immune response against the blood stage of the parasite. Two previous phase I clinical trials, one in naïve European adults and one in malaria-exposed Gabonese adults showed that GMZ2 was well tolerated and immunogenic. Here, we present data on safety and immunogenicity of GMZ2 in one to five year old Gabonese children, a target population for future malaria vaccine efficacy trials.

AB - GMZ2 is a fusion protein of Plasmodium falciparum merozoite surface protein 3 (MSP3) and glutamate rich protein (GLURP) that mediates an immune response against the blood stage of the parasite. Two previous phase I clinical trials, one in naïve European adults and one in malaria-exposed Gabonese adults showed that GMZ2 was well tolerated and immunogenic. Here, we present data on safety and immunogenicity of GMZ2 in one to five year old Gabonese children, a target population for future malaria vaccine efficacy trials.

U2 - 10.1371/journal.pone.0022525

DO - 10.1371/journal.pone.0022525

M3 - Journal article

C2 - 21829466

VL - 6

SP - e22525

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 7

ER -